The TearScience® Solution for MGD, including LipiView®, the Korb Meibomian Gland Evaluator™, and LipiFlow®, are FDA-cleared, validated by large multi-center, randomized, controlled clinical studies.
Randomized, controlled clinical trials of LipiFlow® have shown statistically significant improvements in meibomian gland function. The same studies have also shown significant improvement in patient self-reported dry eye symptoms. The TearScience® Solution for MGD is found in practices across North America and has successfully treated tens of thousands of patients globally.
Clinical trials have shown statistically significant improvement, on average, in the clinical sign of number of meibomian glands yielding clear liquid. The study showed significant improvement, on average, in patient self-reported dry eye symptoms.
The graphs below refer to the results of a nine center, randomized, controlled trial conducted in 2009 reporting clinically meaningful improvement in the primary endpoint of meibomian gland functionality and the secondary endpoint of dry eye symptoms.